Shares in Array Biopharma closed up 23% on Tuesday and have now almost doubled in the year-to-date.
The reason for the latest jump was the Colorado-based company presenting positive results from the interim analysis of the Phase III BEACON CRC trial.
"I believe the results of the trial will be practice-changing"This study is evaluating the combination of Braftovi (encorafenib), a BRAF inhibitor, Mektovi (binimetinib), a MEK inhibitor, and the Merck KGaA (MRK: DE) and Eli Lilly (NYSE: LLY) drug Erbitux (cetuximab), in BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two prior lines of therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze